SOD SCIENCES INC.: CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
SOD Sciences and Vivos Therapeutics (VVOS) announced a strategic partnership. Vivos acquired an 11% stake in SOD and 50% ownership of its pseudohypoxia patent and test for $12M in convertible preferred stock. The companies will jointly market the ReBalU Protocol to Vivos's customers, targeting 500,000 chronic disease patients. SOD retains other patents and protocol rights.
How this was made
The 30-second read
Why it matters
The deal creates a 50/50 ownership of a pseudohypoxia patent and test, potentially expanding Vivos' product suite and revenue.
Market read
First‑report of a $12M strategic investment that could affect Vivos' share price and the broader health‑tech sector.
What to watch
Regulatory clearance for the ReBalU test and reimbursement pathways remain uncertain.
Background
Press release announcing a strategic partnership and equity investment between Vivos Therapeutics and SOD Sciences.
Ticker impact
Vivos Therapeutics acquired an 11% equity stake in SOD Sciences and received $12M of convertible preferred stock in a new strategic partnership.
likely upward pressure as investors price in the new revenue stream and cross‑selling opportunity.
Equity investment and joint commercialization typically boost the investor's share price, especially with a sizable $12M cash infusion.
Market effects
May spur interest in other sleep‑apnea and chronic‑disease diagnostics firms.
U.S. health‑tech sector could see modest uplift.
Limited to U.S. biotech and health‑tech investors.
Counterpoint
The partnership could dilute SOD's focus and Vivos may overpay for a niche test with uncertain adoption.
Key entities
- companyVivos Therapeutics, Inc.
Nasdaq‑listed sleep‑apnea treatment company acquiring stake in SOD Sciences.
- companySOD Sciences, Inc.
Developer of the ReBalU Primed Cell Test and related patents.

